<DOC>
	<DOCNO>NCT00116831</DOCNO>
	<brief_summary>The purpose study test safety effectiveness rosiglitazone sulfonylurea reduce slow development atherosclerosis blood vessel heart .</brief_summary>
	<brief_title>Rosiglitazone Versus Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Glipizide</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<criteria>Inclusion criterion : Male female 30 80 year age , inclusive . Established diagnosis T2DM ( base diagnostic criterion American Diabetes Association ( ADA ) , WHO guideline local national guideline ) . Subjects undergoing coronary angiography evaluation suspect previously diagnose coronary artery disease undergo PCI . Subjects ' prior antihyperglycemic diabetic therapy : Diet exercise ( drug naïve ) , HbA1c &gt; 7.0 £ 10.0 % . HbA1c &gt; 6.5 &lt; = 8.5 % . Left ventricular ejection fraction ( EF ) ³ 40 % assess contrast ventriculography ( previously document medical note within one month prior index procedure method e.g . echocardiography nuclear study ) Female subject must postmenopausal ( i.e. , &gt; 6 month without menstrual period ) , surgically sterile , use effective contraceptive measure ( oral contraceptive , Norplant , DepoProvera , intrauterine device ( IUD ) , diaphragm spermicide condom spermicide ) . Women childbearing potential must use effective contraceptive measure least 1 month prior visit 1a , continue use contraceptive method study 30 day discontinue study medication . Willingness ability give inform consent prior enter study available complete study . Type 1 diabetes and/or history diabetic ketoacidosis . Exposure TZD PPARg agonist within 6 month prior screen visit . Subjects treat triple OAD therapy high dose dual combination OAD therapy [ 1 ] . Subjects require chronic insulin use last 6 month ( except pregnancy acute episodes hospitalization , trauma infection ) . ST segment elevation myocardial infarction last 30 day . Subjects history schedule receive coronary artery bypass graft surgery ( CABG ) , valve repair replacement , aneurysmectomy plan major noncardiac surgery study period . Subjects severe cardiac valvular disease Stroke resuscitate past 6 month History congestive heart failure ( NYHA class I IV ) History significant hypersensitivity reaction ( e.g. , difficulty swallowing , difficulty breathing , tachycardia skin reaction ) TZD , SU , biguanide insulin Prior history severe edema edema require medical treatment . Chronic disease require chronic intermittent treatment oral , intravenous , injected corticosteroid ( use topical , inhaled , nasal corticosteroid permissible ) . Recent history suspicion current drug abuse alcohol abuse within last 6 month . Untreated hypo hyperthyroidism A diagnosis cancer ( superficial squamous , basal cell skin cancer , adequately treated cervical carcinoma situ ) past 3 year current treatment active cancer . Any clinically significant abnormality identify screen visit , physical examination , laboratory test , electrocardiogram , judgement Investigator , would preclude safe completion study . Blood pressure : SBP &gt; 170 DBP &gt; 100 mmHg Significant anemia ( Hemoglobin &lt; 11 g/dL male &lt; 10 g/dL female ) . Significant renal disease manifest serum creatinine ( &gt; 1.5mg/dL male &gt; 1.4mg/dL female ) , use metformin contraindicate . Hepatic disease biliary tract obstruction , significant hepatic enzyme elevation ( ALT AST &gt; 2.5 time upper limit normal ( ULN ) bilirubin &gt; 2x ULN ) . History myopathy history elevate creatine kinase ( CK ) &gt; 3 time upper normal limit . Use investigational drug within 30 day 5 halflives ( whichever longer ) . Women lactate , pregnant planning become pregnant course study . Unwillingness inability comply procedure describe protocol .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>atheroma</keyword>
	<keyword>IVUS</keyword>
	<keyword>Intravascular ultrasound</keyword>
	<keyword>atherosclerosis</keyword>
</DOC>